Nancy Whiting, Pharm.D.
In it for a passion to serve cancer patients.
Nancy brings deep knowledge of all phases of drug development and medical affairs to Seagen. As a clinical leader within our organization for more than a decade, she has made many important scientific contributions to all our programs, including driving the development strategies for ADCETRIS® (brentuximab vedotin) and TUKYSA® (tucatinib). Nancy also previously led our Global Medical Affairs and the Early-Stage Development functions.
Prior to joining Seagen, Nancy was a Senior Oncology Medical Scientist at GlaxoSmithKline and a Clinical Oncology Pharmacist at Seattle Cancer Care Alliance.
Nancy holds a Pharm.D. from the University of Washington and B.Sc. in Pharmaceutical Sciences from the University of British Columbia. She completed her residency in clinical pharmacy practice at the Vancouver General Hospital.